Nutrition, metabolism, and cardiovascular diseases : NMCDNov 21, 2024

Reported Side Effects of Using SGLT2 Inhibitors and GLP-1 Receptor Agonists Together: Real-World Data from FAERS

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

The analysis found that adverse event reporting did not significantly increase for patients using both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) compared to those on monotherapy.

The reporting of SGLT2i-related adverse events, such as diabetic ketoacidosis and urinary tract infections, decreased with combination therapy compared to SGLT2i alone.
No increased risk of fractures was detected in patients using both SGLT2i and GLP1RA.
GLP1RA-related adverse events, including gastrointestinal issues and pancreatitis, also showed a decrease when combined with SGLT2i compared to GLP1RA alone.
An increase in reports of hyperlipasaemia and hyperamylasaemia was noted with the combination therapy.
No signals of depression, suicidal behavior, or self-injury were observed in the combination therapy.

Simplified

BACKGROUND AND AIMS: We evaluate whether the combination of sodium-glucose cotransporter-2 inhibitor(SGLT2i) and glucagon-like peptide-1 receptor agonist(GLP1RA) disproportionally increases the reporting of adverse events compared with SGLT2i or GLP1RA monotherapy in the FDA adverse event reporting system (FAERS).

METHODS AND RESULTS: Adverse events related to SGLT2i and GLP1RA were screened and selected, then data from the FAERS was underwent thorough disproportionality analysis. The proportional reporting ratio(PRR) of SGLT2i-related adverse events were compared between patients using SGLT2i alone and those using both SGLT2i and GLP1RA. Similarly, the PRR of GLP1RA-related adverse events were compared between patients using GLP1RA alone and those using both SGLT2i and GLP1RA. The results showed that the PRR of SGLT2i-related adverse events including diabetic ketoacidosis(DKA), ketosis, reproductive tract adverse events, urinary tract infection, and other adverse events, decreased in individuals using both SGLT2i and GLP1RA compared with those using SGLT2i alone, and the signal of fracture was not detected. Likewise, the PRR of GLP1RA-related adverse events including gastrointestinal adverse events, gallbladder and biliary tract disease, pancreatitis, and other adverse events, decreased in individuals using both SGLT2i and GLP1RA compared with those using GLP1RA alone, the PRR of hyperlipasaemia and hyperamylasaemia increased in the combination therapy and no signal of depression, suicidal and self-injurious behaviour was detected.

CONCLUSION: Adverse events reporting are not disproportionally higher among those using both SGLT-2i and GLP1RA compared with SGLT2i or GLP1RA monotherapy.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest No potential conflicts of interest relevant to this article were reported.

PubMed

Reported Side Effects of Using SGLT2 Inhibitors and GLP-1 Receptor Agonists Together: Real-World Data from FAERS

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief